What Has Been the Growth of the Cancer Monoclonal Antibodies Market So Far?
The cancer monoclonal antibodies market has seen considerable growth due to a variety of factors.
• The market for cancer monoclonal antibodies has seen a swift expansion in recent years. It is projected to rise from $77.88 billion in 2024 to $86.06 billion in 2025, with a compound annual growth rate (CAGR) of 10.5%.
Factors such as emerging market growth, a rise in research and development expenditure, an aging population, and heightened interest in biological treatment options have all contributed to the growth experienced in the historical period.
How Will the Cancer Monoclonal Antibodies Market Size Evolve over the Forecast Period?
The cancer monoclonal antibodies market is expected to maintain its strong growth trajectory in upcoming years.
• The market for cancer monoclonal antibodies is predicted to experience robust growth in the following years, eventually reaching a value of $113.68 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.2%.
This expansion during the projected period is due to the growing incidence of cancer, increased global accessibility, and higher healthcare spending. Main trends for the period forecast include product advancement through strategic partnerships, technological progress, the development of humanized cancer monoclonal antibodies, AI investments aimed at lowering R&D costs and expediting drug development, and R&D investments.
What Factors Are Driving Growth In The Cancer Monoclonal Antibodies Market?
The global increase in cancer cases is expected to stimulate the growth of the cancer monoclonal antibody market. For example, in July 2024, data from the Australian Institute of Health and Welfare, a government agency in Australia, revealed a significant rise in diagnosed cancer cases from 160,570 in 2022 to 164,694 in 2023. This growth illustrates the escalating prevalence of cancer within the nation. Lung, prostate, bowel, and female breast cancer are the most prevalent types globally, comprising 43 percent of all new cancer diagnoses. As such, the climbing cancer incidence rate worldwide is predicted to fuel the demand for the cancer monoclonal antibody market's expansion.
What Key Areas Define The Segmentation Of The Global Cancer Monoclonal Antibodies Market?
The cancer monoclonal antibodies market covered in this report is segmented –
1) By Monoclonal Antibody Therapies: Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta, Others
2) By Application: Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Others
3) By End-User: Hospitals, Research Laboratories, Others
Subsegments:
1) By Avastin: Colorectal Cancer Treatment, Lung Cancer Treatment, Renal Cell Carcinoma Treatment
2) By Herceptin: Breast Cancer Treatment, Gastric Cancer Treatment
3) By Keytruda: Melanoma Treatment, Non-Small Cell Lung Cancer (NSCLC) Treatment, Head And Neck Cancer Treatment
4) By Opdivo: Melanoma Treatment, Renal Cell Carcinoma Treatment, Hodgkin Lymphoma Treatment
5) By Darzalex: Multiple Myeloma Treatment, AL Amyloidosis Treatment
6) By Perjeta: Breast Cancer Treatment, Neoadjuvant Therapy For HER2-Positive Breast Cancer
7) By Others: Cetuximab (Erbitux) For Colorectal And Head And Neck Cancers, Rituximab (Rituxan) For Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia, Atezolizumab (Tecentriq) For Various Cancers
Pre-Book The Cancer Monoclonal Antibodies Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Cancer Monoclonal Antibodies Market?
To remain competitive in the burgeoning cancer monoclonal antibody market, firms are boosting their product innovation via strategic partnerships. They are creating novel products and partnering with other businesses to exchange skills and knowledge. The practice of collaborating with academic and research bodies through partnerships and licensing agreements is becoming more prevalent in this market. For example, BioNTech SE, a biotech research firm located in Germany, teamed up with OncoC4, Inc. in March 2023 to co-develop and distribute a pioneering checkpoint antibody for various solid tumor indications globally. As a result, BioNTech acquired an exclusive global license for the ONC-392 anti-CTLA-4 monoclonal antibody from OncoC4. The companies are expected to conduct a Phase 3 trial in 2023 for solid tumor indications, with plans for BioNTech to explore combination therapies. Additionally, BioNTech will make a $200 Million upfront payment and royalty payments to OncoC4, contingent on meeting certain milestones. OncoC4, Inc. is a US clinical-stage biopharmaceutical firm that focuses on manufacturing biologicals for treating cancer.
Who Are the Key Players in the Cancer Monoclonal Antibodies Market?
Major companies operating in the cancer monoclonal antibodies market include:
• F. Hoffmann-La Roche Ltd
• Merck & Co.. Inc
• Bristol Myers Squibb Company
• Johnson & Johnson
• Amgen Inc
• AstraZeneca plc
• Eli Lilly and Company
• Pfizer Inc
• Regeneron Pharmaceuticals Inc
• Sanofi S.A
• Innovent Biologics
• Sino biological
• Shanghai Henlius Biotech
• Intas bio
• Zydus Cadila
• Ranbaxy
• Takeda pharmaceuticals
• AbbVie Inc
• Biogen Idec
• Bayer AG
• Novartis AG
• BiosanaPharma
• WuXi
• GlaxoSmithKline
• Teva UK Limited
• Abbott Laboratories
• Fujifilm
• Procos SpA
• BSP Pharmaceuticals
• Genmab
• Insysbio
• Gilead Sciences
• Eurofarma
• BIONOVIS BRASIL
• Ache
• Libbs Farmaceutica
• Julphar
• Spimaco Addwaeih
• Hikma Pharmaceuticals
• Tabuk
• Novo Nordisk
• BBI Solutions
• APC Pharma
• EPICIO
• Medical Union Pharmaceuticals
• South Egypt Drug Industries Co. Pharmaceutical
• Vacsera Pharma
• Aspen Pharmacare
• Amoun Pharmaceuticals CO Ltd
• 54gene
• Baxter International
• Altis Biologics
• Cipla Medpro South Africa
• Genzyme
What Is The Most Dominant Region In The Cancer Monoclonal Antibodies Market?
North America was the largest region in the cancer monoclonal antibodies market in 2024. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
